



Release No 332

31 March 2008

**Share Buyback in H. Lundbeck A/S**

Acting on its authorization to acquire up to 10% of its shares, Lundbeck's Supervisory Board has resolved to initiate a share buyback program. Under the program Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 dated 17 August 2005. The buyback program is expected to be completed by the end of 2008.

During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on OMX Nordic Exchange Copenhagen, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003.

At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program.

The following transactions have been made under the program:

	No. of shares	Average purchase price (DKK)	Transaction value (DKK)
Accumulated, last announcement	28,904,462	134.2567	3,880,619,032
18 March 2008	116,000	107.0135	12,413,563.68
19 March 2008	66,200	106.3562	7,040,778.63
25 March 2008	--	--	--
26 March 2008	124,400	111.3456	13,851,398.24
27 March 2008	8,400	112.0560	941,270.40
28 March 2008	129,200	115.6878	14,946,865.70
31 March 2008	8,400	115.0575	966,483.00
Accumulated under the program	29,357,062	133.8955	3,930,779,391



Following the above buyback it is hereby announced that Lundbeck owns a total of 10,200,275 own shares at a nominal value of DKK 5, equal to 4.92% of the total number of 207,279,631 shares.

**Lundbeck contacts**

*Investors:*

Jacob Tolstrup  
Director  
+45 36 43 30 79

Palle Holm Olesen  
Head of Investor Relations  
+45 36 43 24 26

*Media:*

Anders Schroll  
Head of Communication  
+45 36 43 20 81

**Stock Exchange Release No 332 – 31 March 2008**

**About Lundbeck**

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.5 billion or USD 2.0 billion). The number of employees is approximately 5,300 globally. For further information, please visit [www.lundbeck.com](http://www.lundbeck.com)